| ID | 1125 |
| Name of the vaccine | Bexsero |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 10 to 25 years |
| Description of the vaccine | Meningococcal group B Vaccine (MenB Vaccine). |
| Name of the manufacturer | GSK Vaccines |
| Name of the manufacturing country | Sovicille (SI), Italy |
| Year of manufacture | 2015 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | Was assessed by measuring serum bactericidal activity using human complement (hSBA). |
| Vaccine formulation | Suspension 0.5-mL single-dose prefilled syringes. |
| Dosage | 2 doses (0.5-mL each) at least 1 month apart. |
| Mechanism of action | Complement-mediated antibody-dependent killing of N. meningitidis. |
| Route of administration | Intramuscular |
| Indications | To prevent invasive disease caused by Neisseria meningitidis serogroup B. |
| Export | Distributed by - GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | For gonorrhoea also. |
| Side effects of vaccine | Injection site pain, myalgia, erythema, fatigue, headache, induration, nausea and arthralgia. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/90996/download |
| Other name | NA |
| Additional Links | NA
|